Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system to cure diseases from within, has announced the closing of its previously announced acquisition of Twelve Bio ApS, a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas medicines. The closing follows recent clearance by the Danish Business Authority pursuant to Danish foreign direct investment laws.
Read the full article: Ensoma Announces Closing of Twelve Bio Acquisition
Source: https://www.businesswire.com/news/home/20230209005307/en/Ensoma-Announces-Closing-of-Twelve-Bio-Acquisition